Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients

Published:2014-11-18 Issue:2 Volume:33 Page:179-190
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Blank Patricia R.,Filipits Martin,Dubsky Peter,Gutzwiller Florian,Lux Michael P.,Brase Jan C.,Weber Karsten E.,Rudas Margaretha,Greil Richard,Loibl Sibylle,Szucs Thomas D.,Kronenwett Ralf,Schwenkglenks Matthias,Gnant Michael

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s40273-014-0227-x/fulltext.html

Reference55 articles.

1. Schilsky RL. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol. 2009;27(23):3725–30.

2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.

3. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663–71.

4. Hayes DF. Targeting adjuvant chemotherapy: a good idea that needs to be proven! J Clin Oncol. 2012;30(12):1264–7.

5. Wockel A, Kreienberg R. First revision of the German S3 guideline ‘diagnosis, therapy, and follow-up of breast cancer’. Breast Care (Basel). 2008;3(2):82–6.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Krankheitslast von Brustkrebs in Deutschland: Epidemiologie und Kosten;Forum;2023-06-20

2. Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach;Frontiers in Public Health;2023-01-06

3. Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing;Breast Cancer Research and Treatment;2021-12-01

4. Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict);Breast Cancer Research and Treatment;2021-11-16

5. Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach;Human Pathology Reports;2021-11